Cefixime bioavailability of two sus pen sion for mu la tions Ab stract. This in ves ti ga tion was car ried out to eval u ate the bioavailability of a new sus pen sion for mu la tion of cefixime (100 mg/5 ml), Winex, rel a tive to the ref er ence prod uct, Suprax (100 mg/5 ml) sus pen sion. The bioavailability study was car ried out in 24 healthy male vol un teers who re ceived a sin gle oral dose (200 mg) of the test (A) and the ref erence (B) prod ucts on 2 treat ment days af ter an over night fast of at least 10 hours. The treatment pe ri ods were sep a rated by a one-week wash out pe riod. A ran dom ized, bal anced two-way cross over de sign was used. Af ter dos ing, se rial blood sam ples were col lected over a pe riod of 16 hours. Plasma con cen trations of cefixime were an a lyzed us ing a sen sitive high-per for mance liq uid chro matographic as say. The pharmacokinetic pa ram eters for cefixime were de ter mined us ing standard non-compartmental method. The pa rame ters AUC 0-t , AUC 0-∞ , C max , K el , t 1/2 and C max /AUC 0-∞ were an a lyzed sta tis ti cally using raw and log-trans formed data. The time to max i mum con cen tra tion (t max ) was an a lyzed us ing raw data. The para met ric 90% confidence in ter vals of the mean val ues of the pharmacokinetic pa ram e ters: AUC 0-t , AUC 0-∞ , C max , and C max /AUC 0-∞ were within the range 80 -125% which is ac cept able for bioequivalence (us ing log-trans formed data). The cal cu lated 90% con fi dence in ter vals based on the ANOVA anal y sis for the mean test/ref er ence ra tios of AUC 0-t , AUC 0-∞ , C max , and C max /AUC 0-∞ were 88. 93 -107.10%, 89.09 -107.11%, 89.63 -108.58% and 96.85 -105.29%, re spec tively. The test formu la tion was found bioequivalent to the refer ence for mu la tion with re gard to AUC 0-t , AUC 0-∞ , and C max us ing the Schuirmann's two one-sided t-tests. There fore, the two for mu lations were con sid ered to be bioequi valent.
Introduction
Cefixime is an oral third-gen er a tion cephalosporin antibiotic. The drug has been clin ically ef fec tive in treat ing otitis me dia, re spira tory tract in fec tions and un com pli cated uri nary tract in fec tions due to sus cep ti ble organ isms [Micromedex Inc. 2002] . Cefixime has a bioavail abil ity of about 50% [Faulk ner et al. 1988] . Fol low ing oral ad min is tra tion of cefixime with food, the to tal amount absorbed is not al tered but the time to max i mal con cen tra tion is in creased by 0.8 hours [Faulkner et al. 1988 , Jones 1988 , Montay et al. 1991 . Ther a peu tic plasma con cen tra tions for cefixime have not been de fined, but de pending on the dose, peak plasma con cen tra tions of 1 -4 µg/ml or 1.9 -7.7 µg/ml were measured with sin gle or mul ti ple doses of 200 mg and 400 mg, re spec tively [Faulk ner et al. 1988 , Montay et al. 1991 . Peak plasma concen tra tions nor mally oc cur within 2 -6 hours af ter sin gle oral doses [Faulk ner et al. 1988 , Jones 1988 , Montay et al. 1991 . The drug has an elim i na tion half-life of 3 -4 hours, and a rel a tively low pro por tion (15 -20%) of a dose is ex creted by the re nal route [Faulk ner et al. 1988 , Jones 1988 , Micromedex Inc. 2002 . The ob jec tive of this study was to com pare un der fast ing con di tions, the rate and ex tent of ab sorp tion of a ge neric sus pen sion for mula tion of cefixime: Winex sus pen sion (100 mg/5 ml), man u fac tured by Tabuk Phar maceu ti cal Man u fac tur ing Com pany, Tabuk, Saudi Ara bia, rel a tive to the ref er ence for mula tion: Suprax 100 (100 mg/5 ml), man u factured by Hikma Pharmaceuticals Amman, Jor dan. Bioequivalence of the two prod ucts was as sessed based on the plasma con cen tra -tion data ob tained fol low ing their ad min is tration to 24 healthy male vol un teers in a balanced two-way cross over de sign.
Subjects, materials and method

Subjects
Twenty-four healthy male adult vol un teers par tic i pated in the study. The mean age (± SD) of the sub jects was 32.13 ± 6.11 years, with a range of 22 -43 years, mean body weight was 78.58 ± 8.79 kg with a range of 57 -92 kg, and mean height was 174.75 ± 6.00 cm with a range of 161 -188 cm. On the ba sis of med ical his tory, clin i cal ex am i na tion and lab o ratory in ves ti ga tion (he ma tol ogy, blood biochem is try and uri nal y sis), no sub ject had a his tory or ev i dence of hepatic, re nal, gas troin tes ti nal or hematologic de vi a tions or any acute or chronic dis eases or al lergy to ce fixime or other β-lactam an ti bi ot ics. The vol un teers were asked to ab stain from tak ing any drug in clud ing over-the-coun ter (OTC) for two weeks prior to and dur ing the study. The volun teers were in formed about the risk and aim of the study by the clin i cal in ves ti ga tor and signed a writ ten in formed con sent state ment be fore en ter ing the study. The vol un teers were free to with draw from the study at any time. The study pro to col was ap proved by King Khalid Uni ver sity Hos pi tal, King Saud Uni ver sity, Ri yadh, Saudi Ara bia. 
Study protocol
Study design and blood samples
The ad min is tra tion of the two prod ucts to the sub jects was car ried out by means of a two-way cross over de sign with one-week wash out pe riod be tween each treat ment phase. Sub jects were ran domly di vided into two equal groups and as signed to one of the two se quences of drug ad min is tra tion. Each sub ject re ceived a sin gle oral dose of 10 ml sus pen sion (200 mg) of ei ther brand (A or B) af ter a su per vised over night fast for at least ten hours. The dose was given by the use of 10 ml sy ringe and the sy ringe was filled with 10 ml wa ter 3 times and given to the vol un teer fol lowed by 200 ml of wa ter. Sub jects were given a stan dard break fast at 4 hours, lunch 9 hours, and din ner at 14 hours af ter drug admin is tra tion. Bev er ages and food con tain ing caf feine were not per mit ted over the en tire course of the study. Vol un teers were am bu latory dur ing the study but were pro hib ited from stren u ous ac tiv ity. For the pe riod of 16 hours fol low ing drug ad min is tra tion, the volun teers were un der di rect med i cal super vision in the clinical study site at King Khalid University Hospital.
Mul ti ple ve nous blood sam ples (10 ml) were col lected in evac u ated glass tubes (heparinized vacutainer, Beckton and Dickinson, Rutherford, NJ, USA), through an indwell ing can nula placed in the fore arm veins or di rectly from the vein be fore (0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 14.0 and 16.0 hours af ter drug ad min is tra tion. The blood was then slightly shaken and cen tri fuged at 900 × g for ten min utes and the plasma was de canted in coded poly propy lene tubes and stored frozen at -20 °C pending drug analysis.
Analysis of plasma samples
The con cen tra tions of cefixime in plasma were mea sured by a sen si tive, se lec tive, ac curate and val i dated high-per for mance liq uid chro ma tog ra phy (HPLC) method [Asiri et al. 2004 ] us ing UV de tec tion at 280 nm. The val i da tion procedure fol lowed in ter na tional guide lines [FDA 2001] . The pro ce dure involves pro tein pre cip i ta tion with 12.5% trichloroacetic acid (TCA). The drug and the internal stan dard (coumarin) were eluted from a 5 µm stain less steel Supercosil C18 co lumn (4.6 × 150 mm) (Wa ter As so ci a tion, USA) with an av er age par ti cle size of 5 µm at room tem per a ture with isocratic mo bile phase consist ing of 10% acetonitrile in 0.05 M po tas -sium dihydrogen phos phate buffer (pH 3.0), at a flow rate of 2 ml/min, and mon i tored in a UV de tec tor set at 280 nm. Each anal y sis required no lon ger than 12 min. Quantitation was achieved by mea sure ment of the peak area ra tio of the drug to the in ter nal stan dard, and the limit of quan ti fi ca tion for cefixime was 0.1 µg/ml from 0.25 ml plasma.
The intraday ac cu racy of the method for cefixime ranged from 96.00 -100.52%, while the intra day pre ci sion ranged from 0.74 -5.83%. The interday ac cu racy ranged from 96.00 -99.43%, while the interday preci sion ranged from 2.99 -5.63%. The ab solute an a lyt i cal re cov ery of cefixime was 75.94% and for the in ter nal stan dard (cou marin) was 63.94%. The rel a tive an a lyt i cal re covery of cefixime ranged from 93.93 -97.59%. Sta bil ity study showed that cefixime is sta ble (short -term room tem per a ture) for 4 hours, cefixime is sta ble (af ter preparation) for 16 hours at room tem per a ture and for 16 hours at -20 °C. Cefixime is sta ble for 3 cy cles of freeze and thaw, when stored at -20 °C and thawed at room tem per a ture. The stock so lutions of cefixime and the in ter nal stan dard are sta ble at room tem per a ture for 6 hours and at -20 °C for 2 weeks. Cefixime is sta ble in plasma (long-term) for more than 4 weeks when stored at -20 °C.
Pharmacokinetic analysis
The pharmacokinetic pa ram e ters for cefixime were es ti mated by stan dard noncompartmental meth ods. All pa ram e ters were de ter mined from the true (ac tual) sam ple collec tion times and as sayed plasma con cen trations at these times. The max i mum plasma con cen tra tion (C max ) and the time to reach plasma con cen tra tion (t max ) were ob tained from the in di vid ual plasma concentrationtime data and used as mea sures of rate of absorp tion. The area un der the plasma con centra tion time curve up to the last time (t) showing a quan ti fi able con cen tra tion (C t ) of the analyte (AUC 0-t ) was de ter mined us ing lin ear trap e zoidal rule. The elim i na tion half-life (t 1/2 ) was cal cu lated us ing the fol low ing equa tion:
where K el is the ap par ent elim i na tion rate con stant and was ob tained as the slope of the lin ear re gres sion of the ln-trans formed plasma con cen tra tion ver sus time data in the termi nal phase of the plasma con cen tra tion-time curve. The area un der the plasma con cen tration-time curve (AUC 0-t ) was cal cu lated from Cefixime bioavailability of two sus pen sion for mu la tions 501 Ta ble 1. Mean pharmacokinetic char ac ter is tics for cefixime af ter ad min is tration of the two for mu la tions to 24 sub jects. Geo met ric mean = exp (mean (ln)), range = exp (mean (ln) ± SD (ln)), the pharmacokinetic char ac ter is tic AUC 0-t , AUC 0-∞ , C max , K el , t 1/2 and C max / AUC 0-∞ were de ter mined based on a multi pli ca tive model, t max was an a lyzed as sum ing ad di tive model.
Ta ble 2. Para met ric and non-para met ric 90% con fi dence in ter vals (us ing log-trans formed data) for the mean pharmacokinetic char ac ter is tics of cefixime for mu la tions.
Pa ram e ter A/B point Con fi dence lim its Level of con fi dence es ti mate the mea sured data points from time zero to time of last quan ti fi able con cen tra tion by the lin ear trap e zoidal rule. The area un der the plasma con cen tra tion-time curve ex trap olated to in fin ity (AUC 0-∞ ) was cal cu lated according to the following formula:
where C t is the last quan ti fi able plasma con cen tra tion. The rate of ab sorp tion of cefixime from the two brands was also eval uated by means of the ra tio: C max /AUC 0-∞ . This ra tio is con sid ered a good pa ram e ter for evalu at ing the ab sorp tion rates in bioequivalence stud ies of im me di ate re lease for mu la tions [Schall and Luus 1992] . The ra tio AUC 0-t / AUC 0-∞ was de ter mined as an in di ca tor for the ad e quacy of the sam pling times. The pharma cokinetic cal cu la tions were per formed on a per sonal com puter us ing the pro gram Micro soft Ex cel (Ver sion 7.0, Micro soft Co., Redmond, WA, USA). The equa tions were entered into the pro gram man u ally and checked by two in ves ti ga tors.
Statistical analysis
The two-way anal y sis of vari ance (ANO -VA) for cross over de sign was used to as sess the ef fect of for mu la tions, pe ri ods, se quences and sub jects within se quence on the raw ( untransformed) and logarithmically transformed data of AUC 0-t , AUC 0-∞ , C max , K el , t 1/2 , and C max /AUC 0-∞ pa ram e ters. The ANO -VA o f t max was car ried out on the un transformed data. Se quence ef fects were tested against the mean square term for sub jects within se quence. All other main ef fects were tested against the mean square er ror term. Cefixime plasma con cen tra tions at each sam pling time point were also an a lyzed sta tis ti cally us ing anal y sis of vari ance. Para met ric 90% con fidence in ter vals based on the ANO VA of the mean test/ref er ence ra tios of AUCs pa ram eters and C max were com puted un der the assump tion of multi pli ca tive model us ing logtransformed data. It is widely ac cepted among biometricians that es tab lish ing the con fi dence in ter vals rather than hy poth e sis test ing is ap pro pri ate for sta tis ti cal eval u a tion of bioequivalence Diletti 1983, West lake 1972] . In ad di tion, bioequivalence be tween the two for mu la tions was also as sessed by Schuirmann's two one-sided t-tests pro ce dure [Schuirmann 1987 ]. Tests for nor mal ity of intrasubject vari abil ity were per formed by cal cu la tion of the intrasubject re sid u als dur ing Period 1 and Period 2 ir respec tive of the for mu la tion, and univariate anal y ses were per formed for AUC 0-t , AUC 0-∞ and C max pa ram e ters. These tests were car ried out to screen for ex treme out li ers and de partures from nor mal ity. Intrasubject re sid u als were es ti mated by com put ing the dif fer ence be tween the ob served and pre dicted val ues and any sub ject was con sid ered out lier if extremely large or small un usual value was obtained.
For all anal y ses, ef fects were con sid ered sta tis ti cally sig nif i cant if the prob a bil ity as soci ated with F was ≤ 0.05. All anal y ses of the data were per formed with the sta tis ti cal software pack age Sta tis ti cal Anal y sis Sys tem (SAS) us ing the Gen eral Lin ear Model Pro cedure (SAS Institute Inc., Cary, NC, USA).
Results and discussion
The 2 for mu la tions were well-tol er ated in all sub jects, un ex pected in ci dents that could have in flu enced the out come of the study did not oc cur. There was no drop-out and all subjects who started the study con tin ued to the end and were dis charged in good health.
Cefixime was mea sur able at the first sampling time (0.5 h) in all sub jects fol low ing admin is tra tion of Winex and in 23 sub jects following ad min is tra tion of Suprax 100. Plas - Fig ure 1 . Mean plasma con cen tra tion-time profiles of cefixime fol low ing oral ad min is tra tion of two brands to 24 healthy male vol un teers. ma con cen tra tions at the last sam pling time (16 hours), were be low 0.1 µg/ml (lower quan ti fiable con cen tra tion) in one sub ject follow ing ad min is tra tion of the two for mu lations. The mean plasma con cen tra tion-time curves for the two brands are de picted in Figure 1 . It can be seen that the mean plasma concen tration-time pro files from brand A and B are al most superimposable; 17 ANOVAs were per formed to com pare cefixime plasma con cen trations pro duced by the two for mu lations at each sam pling time. There was no statis ti cal dif fer ence be tween the two for mu lations at all sam pling time points. The pa ram e ters used to mea sure bioavailability were AUC 0-t , AUC 0-∞ , for the ex tent of absorp tion and C max , t max , C max /AUC 0-∞ for the ab sorp tion rate and they were cal cu lated in a model-in de pend ent man ner. Table 1 shows the geo met ric mean val ues and the range for the above parameters (AUC 0-t , AUC 0-∞ , C max , C max / AUC 0-∞ ) along with K el and t 1/2 . The phar macokinetic pa ram e ter t max is pre sented as a median (range). The rel a tive bioavailability (mean per cent age of in di vid ual ra tios) of the ge neric for mu la tion was found to be 101.3%, 101.2%, 102.7% based on AUC 0-t , AUC 0-∞ , and C max , re spec tively. The cal cu lated pharmacokinetic pa ram e ters of cefixime are in agree ment with pre vi ously re ported val ues [Faulk ner et al. 1989 , Montay et al. 1991 , Nix et al. 1997 . Re sults of the ANOVA of the bioavailability data showed that there were no sig nif i cant dif fer ences be tween for mu la tions on all of the pharma co kinetic pa ram e ters. Fur ther more, pe ri ods and se quence ef fects did not in flu ence the out come of the sta tis ti cal anal y sis. The intra individual vari a tions in the pharma cokinetic pa ram e ters: AUC 0-t , AUC 0-∞ , C max , t max , K el , t 1/2 and C max /AUC 0-∞ es ti mated from the co ef fi cients of vari a tion as de ter mined by ANOVA were: 18.30%, 18.49%, 18.51%, 13.64%, 11.19%, 11.80% and 8.43%, re spec tively. Sta tis ti cal anal y ses were per formed for AUC 0-t , AUC 0-∞ and C max to screen for ex treme out li ers and de par ture from nor mal ity us ing univariate anal y sis and by cal cu la tion of intrasubject re sid u als (tests for nor mal ity of intrasubject vari abil ity). None of these tests re vealed sig nif i cant outliers dur ing the two dif fer ent pe ri ods of admin is tra tion of the two for mu la tions.
Cefixime is a drug with an intermediateto-low intrasubject vari abil ity (ANOVA-CV of C max and AUC ≤ 20%). The method of Hauschke et al. [1992] for sam ple size de termi na tion for bioequivalence as sess ment using a multi pli ca tive model was used. For the most vari able parameter (C max ) and mean (test/ref er ence) ra tio = 0.95, the re quired sam ple size was de ter mined to be 16 sub jects. The study was per formed us ing 24 sub jects and that gave the test a power of > 90%.
Ta ble 2 shows the para met ric 90% con fidence in ter vals of the mean val ues of the pharmacokinetic pa ram e ters: AUC 0-t , AUC 0-∞ , C max and C max /AUC 0-∞ , re spec tively, as well as the point es ti mates for A/B ra tio as sum ing multi pli ca tive mod els (us ing log-trans formed data). Non-para met ric con fi dence in ter vals were also in cluded. The con fi dence lim its for the mean AUC 0-t , AUC 0-∞ , C max and C max /AUC 0 -∞ in di cate that these val ues are en tirely within the bioequivalence ac cept able range of 80 -125%. Fur thermore, Schuirmann's pro ce dure us ing con fi dence in ter val ap proach con firmed the con clu sion.
